

Centrose to Present at BIO Mid-America

Centrose will present for the first time in a public forum

MADISON, Wis., Sept 24, 2007 – Centrose today announced that it will present at the BIO Mid-America Fifth Annual Venture Forum which is being held Sept. 24-26 at the Hyatt Regency in Milwaukee. James Prudent, Centrose's chief executive, will make the company's presentation on Wednesday, Sept. 26, 2007, at 2:15 p.m. CST.

About Centrose LLC

Centrose, a Madison, Wis.-based biopharmaceutical company, is applying scientific breakthroughs in sugar chemistry to the discovery, development and commercialization of small molecule therapeutics. Centrose delivers commercially relevant technology for the attachment of any sugar molecule to any compound. Sugars are critical to the regulation of biological processes and pathways in the human body, and play fundamental roles in drug action. Naturally derived drugs such as erythromycin, a commonly used antibiotic, that contain sugar molecules have been found to be inactive after the sugars were removed and enhanced in activity when new sugars were added. Centrose owns exclusive chemistry that will allow its chemists to exploit the power of sugar chemistry in much the same way that nature does. Recent data suggests that new drugs containing sugar attachments will find their way to market more quickly, since fewer failures are expected. Centrose owns a broad set of patents and patent applications issued and filed by the Wisconsin Alumni Research Foundation.

Contacts:

James Prudent, Ph.D.
Chief Executive Officer,
Centrose LLC
(608) 209-8933